newsfilter
← Latest News
Business Wire·

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

  • Natera Inc. & Incyte have entered a clinical collaboration for a new phase II colorectal cancer (CRC) trial.
  • The trial, named TOMR (Treatment on MRD), evaluates Incyte's investigational bispecific immunotherapy INCA33890 in patients with stage 2/3 CRC.
  • Eligible participants must have completed surgery & adjuvant chemotherapy (ACT) prior to enrollment.
  • Signatera™ is utilized as both a primary & secondary endpoint, with longitudinal testing conducted for up to 12 months post-ACT.
  • Patients testing Signatera MRD-positive with no radiographic disease evidence after ACT are eligible for the study.
  • Natera provided clinical evidence & MRD-guided trial design expertise to inform the study strategy.
  • Natera will provide trial matching services to identify & enroll patients based on Signatera MRD status & other criteria.
  • The collaboration aims to enable early identification of high-risk recurrence patients & improve outcomes before radiographic progression occurs.
  • Natera operates ISO 13485-certified & CAP-accredited CLIA laboratories in Austin, San Carlos, & Boulder.